Abbott Secures Conditional EU Approval for Solvay Drugs Acquisition

Abbott Laboratories has secured conditional EU approval for the acquisition of the drug unit of Solvay. Abbott will need to divest the cystic fibrosis testing business of Solvay pharma's subsidiary Innogenetics in Europe, as part of the approval. The European Commission said it had concerns that the combined market share in cystic fibrosis testing could harm competition. Abbott announced last September that it had agreed to buy Solvay's pharma business for €4.5 billion ($6.2 billion). The move will transform Solvay from a chemical-pharmaceutical hybrid...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers